Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery

Bioconjugate Chemistry

Volumn 19, Issue 1, 2008, Pages 334-341

  Su, Young Chae ^a   Jin, Cheng Hao ^a   Han, Jong Shin ^a   Yu, Seok Youn ^b   Lee, Seulki ^c   Kang, Choon Lee ^a  

^a Sungkyunkwan University   (South Korea)

^b Pusan National University   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; MACROGOL; TRYPSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTINYLATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG INDICATION; DRUG SYNTHESIS; GLUCOSE TOLERANCE TEST; IN VITRO STUDY; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INTESTINE ABSORPTION; INTESTINE FLUID; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET CELL; RAT;

MUS; RATTUS;

EID: 38949154100     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc700292v     Document Type: Article

References (32)

1. Kieffer, T. J., and Habener, J. F. (1999) The glucagon-like peptides. Endocr. Rev. 20, 876-913.
2. Meier, J. J., and Nauck, M. A. (2005) Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab. Res. Rev. 21, 91-117.
3. Deacon, C. F. (2004) Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53, 2181-2189.
4. Gutniak, M. K., Linde, B., Holst, J. J., and Efendic, S. (1995) Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17, 1039-1044.
5. Dupre, J., Ross, S. A., Watson, D., and Brown, J. C. (1973) Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab. 37, 826-828.
6. Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., Wilding, J. P., Smith, D. M., Ghatei, M. A., Herbert, J., and Bloom, S. R. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature (London) 379, 69-72.
7. Xu, G., Stoffers, D. A., Habener, J. F., and Bonner-Weir, S. (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48, 2270-2276.
8. Stoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Egan, J. M., Bonner-Weir, S., and Habener, J. F. (2000) Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49, 741-748.
9. Zander, M., Madsbad, S., Madsen, J. L., and Holst, J. J. (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359, 824-830.
10. Kieffer, T. J., McIntosh, C. H., and Pederson, R. A. (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136, 3585-3596.
11. Mentlein, R., Gallwitz, B., and Schmidt, W. E. (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214, 829-835.
12. Vilsbøll, T., Agerso, H., Krarup, T., and Holst, J. J. (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol. Metab. 88, 220-224.
13. Yoo, B. K., Triller, D. M., and Yoo, D. J. (2006) Exenatide: a new option for the treatment of type 2 diabetes. Ann. Pharmacother. 40, 1777-1784.
14. Madsbad, S., Schmitz, O., Ranstam, J., Jakobsen, G., and Matthews, D. R. (2004) Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 27, 1335-1342.
15. Hamman, J. H., Enslin, G. M., and Kotzé, A. F. (2005) Oral delivery of peptide drugs: barriers and developments. BioDrugs 19, 165-177.
16. Goldberg, M., and Gomez-Orellana, I. (2003) Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discovery 2, 289-295.
17. Lee, Y., Nam, J. H., Shin, H. C., and Byun, Y. (2001) Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. Circulation 104, 3116-3120.
18. Kim, S. K., Lee, E. H., Vaishali, B., Lee, S., Lee, Y. K., Kim, C. Y., Moon, H. T., and Byun, Y. (2005) Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates. J. Controlled Release 105, 32-42.
19. Chalasani, K. B., Russell-Jones, G. J., Yandrapu, S. K., Diwan, P. V., and Jain, S. K. (2007) A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J. Controlled Release 117, 421-429.
20. Balamurugan, K., Ortiz, A., and Said, H. M. (2003) Biotin uptake by human intestinal and liver epithelial cells: role of the SMVT system. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G73-77.
21. Chatterjee, N. S., Kumar, C. K., Ortiz, A., Rubin, S. A., and Said, H. M. (1999) Molecular mechanism of the intestinal biotin transport process. Am. J. Physiol. 277, C605-613.
22. Ramanathan, S., Pooyan, S., Stein, S., Prasad, P. D., Wang, J., Leibowitz, M. J., Ganapathy, V., and Sinko, P. J. (2001) Targeting the sodium-dependent multivitamin transporter (SMVT) for improving the oral absorption properties of a retro-inverso Tat nonapeptide. Pharm. Res. 18, 950-956.
23. Minko, T., Paranjpe, P. V., Qiu, B., Lalloo, A., Won, R., Stein, S., and Sinko, P. J. (2002) Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol. 50, 143-150.
24. Ramanathan, S., Qiu, B., Pooyan, S., Zhang, G., Stein, S., Leibowitz, M. J., and Sinko, P. J. (2001) Targeted PEG-based bioconjugates enhance the cellular uptake and transport of HIV-1 TAT nonapeptide. J. Controlled Release 77, 199-212.
25. Lee, S. H., Lee, S., Youn, Y. S., Na, D. H., Chae, S. Y., Byun, Y., and Lee, K. C. (2005) Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjugate Chem. 16, 377-382.
26. Lee, S., Youn, Y. S., Lee, S.-H., Byun, Y., and Lee, K. C. (2006) PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. Diabetologia 49, 1608-1611.
27. Youn, Y. S., Chae, S. Y., Lee, S., Jeon, J. E., Shin, H. G., and Lee, K. C. (2007) Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochem. Pharmacol. 73, 84-93.
28. Kim, S., and Bae, Y. H. (2004) Long-term insulinotropic activity of glucagon-like peptide-1/polymer conjugate on islet microcapsules. Tissue Eng. 10, 1607-16.
29. Kim, S., Kim, S. W., and Bae, Y. H. (2005) Synthesis, bioactivity and specificity of glucagon-like peptide-1 (7-37)/polymer conjugate to isolated rat islets. Biomaterials 26, 3597-606.
30. Youn, Y. S., and Lee, K. C. (2007) Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12). Bioconjugate Chem. 18, 500-506.
31. Youn, Y. S., Na, D. H., and Lee, K. C. (2007) High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation. J. Controlled Release 117, 371-379.
32. Jia, X., Brown, J. C., Ma, P., Pederson, R. A., and McIntosh, C. H. (1995) Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion. Am. J. Physiol. 268, E645-651.